KLOWresearch overview.

Overview

KLOW is not a single compound. Each vial holds four separate research compounds: the three in GLOW, namely GHK-Cu ¹, BPC-157 ² and TB-500 (Ac-LKKTETQ) ³, plus KPV, the tripeptide Lys-Pro-Val from the C-terminus of α-⁠melanocyte-stimulating hormone ⁴.

The components are not chemically linked. Research on each is summarised in its own overview. This page covers only what is specific to the blend.

Components

GHK-Cu, 50 mg: Gly-His-Lys · Cu²⁺. Molecular formula C14H22CuN6O4, molecular weight 401.9 g/mol, CAS 49557-75-7.

BPC-157, 10 mg: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular formula C62H98N16O22, molecular weight 1419.5 g/mol, CAS 137525-51-0.

TB-500, 10 mg: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. Molecular formula C38H68N10O14, molecular weight 889.0 g/mol, CAS 885340-08-9.

KPV, 10 mg: Lys-Pro-Val. Molecular formula C16H30N4O4, molecular weight 342.4 g/mol, CAS 67727-97-3.

By number of molecules, the 5:1:1:1 mass ratio corresponds to about 18 GHK-Cu, 1.6 TB-500 and 4.1 KPV for each BPC-157. The batch certificate reports identity and purity for each component separately.

GHK binds copper(II) strongly ¹. KPV, like the other peptides, has a free N-terminal amine that can interact with metal ions. Whether copper exchanges between components in this mixture has not been reported.

What has been studied

This summary found no published study of these four compounds together, or of KPV combined with any of the other three. A PubMed search for GHK or GHK-Cu combined with BPC-157, TB-500, thymosin or KPV returned only narrative reviews that discuss the compounds separately.

The only combination study found for any of these components is a rat study of BPC-157 and TB-500 given separately and together ⁵. It did not include GHK-Cu or KPV, and it is described in the BPC-TB overview.

Research areas

• Copper(II) coordination chemistry of GHK (in vitro) ¹
• BPC-157 literature and patent review (review) ²
• Identity of the TB-500 component as Ac-LKKTETQ (analytical) ³
• First study of the α-⁠MSH(11⁠–⁠13) tripeptide, KPV (animal) ⁴
• BPC-157 and TB-500 given together in a rat model, without GHK-Cu or KPV (animal) ⁵

Limits of the evidence

No published study has tested this combination. Findings for any single component, described in the GHK-Cu, BPC-157, TB-500 and KPV overviews, should not be assumed to apply to the blend.

Whether the four components interact in solution or in an experimental system has not been reported.

OzPept’s KLOW is a research chemical, not a medicine or cosmetic, and is not for human use.

Key studies

1. 1989Animal

   First study of the KPV tripeptide ⁴

2. 2011In vitro

   Copper(II) coordination of GHK ¹

3. 2012In vitro

   Ac-LKKTETQ identified in a TB-500 product ³

4. 2025Review

   BPC-157 literature and patent review ²

5. 2026Animal

   BPC-157 and TB-500 together in rats, without GHK-Cu or KPV ⁵

Questions

References

1. Hureau C, Eury H, Guillot R, Bijani C, Sayen S, Solari PL, Guillon E, Faller P, Dorlet P. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-10160. Source
2. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals. 2025;18(2):185. Source
3. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. Source
4. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284. Source
5. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. Source